Skip to content

Other Inventory, Net at other companies

BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX

Other financials

Income statement

See full
Revenue$14.4M+65.7%
Gross profit$11.0M+117%
Operating income-$4.2M+78.3%
Net income-$8.1M+64.9%
EPS (diluted)-$0.07+70.8%

Balance sheet

See full
Cash & equivalents$110.7M+61.3%
Total debt$64.4M+7.4%
Total equity-$34.1M+44.1%
Total assets$141.1M+38.0%

Cash flow

See full
Operating cash flow-$14.8M+36.7%
CapEx$52.0K-61.5%
Free cash flow-$14.9M+36.9%

Valuation

See full
Market cap$560.13M+73.5%
Enterprise value$513.76M+63.6%
P/S11.1×+5.2×

Profitability

See full
Gross margin63.5%-4.9pp
Operating margin-111.2%+96.3pp
Net margin-137.1%+80.7pp
FCF margin-88.2%-2.2pp

Returns & leverage

See full
Return on equity145.1%
Debt / equity-1.9×
Current ratio4.1×-0.8×

Where this comes from

Reported directly by Aquestive Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxAssetsInventory.

The official record: Aquestive Therapeutics, Inc.’s 10-K, filed March 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aquestive Therapeutics, Inc.'s other inventory, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aquestive Therapeutics, Inc.'s other inventory, net?
Aquestive Therapeutics, Inc. (AQST) reported other inventory, net of $435K in Q4 2025.
What is the long-term trend for Aquestive Therapeutics, Inc.'s other inventory, net?
Over 2 years (2023 to 2025), Aquestive Therapeutics, Inc.'s other inventory, net has grown at a 12.3% compound annual growth rate (CAGR), from $345K to $435K.